These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37861452)

  • 1. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
    Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM
    Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
    Kelly WK; Danila DC; Lin CC; Lee JL; Matsubara N; Ward PJ; Armstrong AJ; Pook D; Kim M; Dorff TB; Fischer S; Lin YC; Horvath LG; Sumey C; Yang Z; Jurida G; Smith KM; Connarn JN; Penny HL; Stieglmaier J; Appleman LJ
    Cancer Discov; 2024 Jan; 14(1):76-89. PubMed ID: 37861461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
    Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
    Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer.
    Hage Chehade C; Gebrael G; Agarwal N
    Cancer Discov; 2024 Jan; 14(1):20-22. PubMed ID: 38213299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
    Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK
    Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
    Lin TY; Park JA; Long A; Guo HF; Cheung NV
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34497115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
    Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using
    Carrasquillo JA; Fine BM; Pandit-Taskar N; Larson SM; Fleming SE; Fox JJ; Cheal SM; O'Donoghue JA; Ruan S; Ragupathi G; Lyashchenko SK; Humm JL; Scher HI; Gönen M; Williams SP; Danila DC; Morris MJ
    J Nucl Med; 2019 Nov; 60(11):1517-1523. PubMed ID: 31053681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
    Penny HL; Hainline K; Theoharis N; Wu B; Brandl C; Webhofer C; McComb M; Wittemer-Rump S; Koca G; Stienen S; Bargou RC; Hummel HD; Loidl W; Grüllich C; Eggert T; Tran B; Mytych DT
    Front Immunol; 2023; 14():1261070. PubMed ID: 37942314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
    Zorko NA; Ryan CJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Biodistribution of a [
    O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
    Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer.
    Jin Y; Lorvik KB; Jin Y; Beck C; Sike A; Persiconi I; Kvaløy E; Saatcioglu F; Dunn C; Kyte JA
    Mol Ther Oncolytics; 2022 Sep; 26():189-206. PubMed ID: 35860008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
    Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
    Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
    Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII.
    Sternjak A; Lee F; Thomas O; Balazs M; Wahl J; Lorenczewski G; Ullrich I; Muenz M; Rattel B; Bailis JM; Friedrich M
    Mol Cancer Ther; 2021 May; 20(5):925-933. PubMed ID: 33632870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
    Danila DC; Szmulewitz RZ; Vaishampayan U; Higano CS; Baron AD; Gilbert HN; Brunstein F; Milojic-Blair M; Wang B; Kabbarah O; Mamounas M; Fine BM; Maslyar DJ; Ungewickell A; Scher HI
    J Clin Oncol; 2019 Dec; 37(36):3518-3527. PubMed ID: 31689155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
    Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
    Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STEAP1 is overexpressed in cancers: a promising therapeutic target.
    Moreaux J; Kassambara A; Hose D; Klein B
    Biochem Biophys Res Commun; 2012 Dec; 429(3-4):148-55. PubMed ID: 23142226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.